ezyVet vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cloud Veterinary Practice Management & Client Engagement
Cloud vet practice management acquired by IDEXX; Auckland New Zealand; 5,000+ clinics in US, Australia, NZ, and UK; covers patient check-in through invoicing and end-of-day reconciliation.
About
ezyVet is a cloud-based veterinary practice management and client engagement platform that provides veterinary clinics with patient records, scheduling, invoicing, billing, client communication, and analytics in a fully browser-based system, headquartered in Auckland, New Zealand and acquired by IDEXX Laboratories — the global veterinary diagnostics leader — in 2021 to extend IDEXX's software platform capabilities alongside its diagnostic products. ezyVet serves more than 5,000 veterinary clinics globally with particular strength in the United States, Australia, New Zealand, and the United Kingdom.\n\nezyVet's platform provides a comprehensive clinical workflow covering patient check-in, consultation and treatment planning, prescription management, invoicing, and end-of-day reconciliation. The two-way client communication features include automated appointment reminders via SMS and email, post-visit summaries, and a client portal where pet owners can access records and request appointments. Deep integration with IDEXX's diagnostic products — including in-clinic analyzers, reference laboratory services, and imaging systems — allows results to flow directly into patient records, providing a significant competitive advantage now that IDEXX owns the platform.\n\nAs an IDEXX-owned platform, ezyVet benefits from IDEXX's global distribution network, integration with IDEXX's full diagnostics portfolio, and the ability to bundle software with diagnostic equipment and service agreements. ezyVet competes with Provet Cloud, Vetspire, Digitail, and the legacy IDEXX Cornerstone platform in the veterinary software market. IDEXX's ownership creates both an advantage (deep diagnostics integration) and a competitive consideration for clinics that use non-IDEXX diagnostic products.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.